These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Vollenweider FX; Preller KH Nat Rev Neurosci; 2020 Nov; 21(11):611-624. PubMed ID: 32929261 [TBL] [Abstract][Full Text] [Related]
3. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Vollenweider FX; Kometer M Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121 [TBL] [Abstract][Full Text] [Related]
4. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. Kraehenmann R Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125 [TBL] [Abstract][Full Text] [Related]
5. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. Canal CE Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180 [TBL] [Abstract][Full Text] [Related]
6. More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics. Aqil M; Roseman L Neuropharmacology; 2023 Feb; 223():109300. PubMed ID: 36334767 [TBL] [Abstract][Full Text] [Related]
7. Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care. Yaden DB; Earp BD; Griffiths RR Camb Q Healthc Ethics; 2022 Oct; 31(4):464-471. PubMed ID: 36398520 [TBL] [Abstract][Full Text] [Related]
9. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Johnson MW; Hendricks PS; Barrett FS; Griffiths RR Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880 [TBL] [Abstract][Full Text] [Related]
10. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Majić T; Schmidt TT; Gallinat J J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401 [TBL] [Abstract][Full Text] [Related]
11. Psychedelics: Where we are now, why we got here, what we must do. Belouin SJ; Henningfield JE Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779 [TBL] [Abstract][Full Text] [Related]
12. [Neuroscientific and psychological explanations for the therapeutic effects of psychedelics]. van Elk M Tijdschr Psychiatr; 2020; 62(8):677-683. PubMed ID: 32816296 [TBL] [Abstract][Full Text] [Related]
13. Phenomenology, Structure, and Dynamic of Psychedelic States. Preller KH; Vollenweider FX Curr Top Behav Neurosci; 2018; 36():221-256. PubMed ID: 28025814 [TBL] [Abstract][Full Text] [Related]
15. The Therapeutic Potential of Psilocybin. Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L Molecules; 2021 May; 26(10):. PubMed ID: 34063505 [TBL] [Abstract][Full Text] [Related]
16. Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis. Dourron HM; Strauss C; Hendricks PS Pharmacol Rev; 2022 Oct; 74(4):982-1027. PubMed ID: 36113878 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808 [TBL] [Abstract][Full Text] [Related]
18. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice. Gobbi G; Inserra A; Greenway KT; Lifshitz M; Kirmayer LJ Transcult Psychiatry; 2022 Oct; 59(5):718-724. PubMed ID: 36263521 [TBL] [Abstract][Full Text] [Related]
19. An introduction to psychedelic neuroscience. Calvey T; Howells FM Prog Brain Res; 2018; 242():1-23. PubMed ID: 30471677 [TBL] [Abstract][Full Text] [Related]
20. Serotonergic psychedelics temporarily modify information transfer in humans. Alonso JF; Romero S; Mañanas MÀ; Riba J Int J Neuropsychopharmacol; 2015 Mar; 18(8):. PubMed ID: 25820842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]